Some Common Post-Merger Compliance Issues
This article was originally published in The Gold Sheet
Executive Summary
Merging drug makers sometimes try to make do with minimal staffing of quality and compliance units – with unfortunate results, FDA’s Edwin Rivera-Martinez told the PDA/FDA conference in Washington last month.